Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | electroCore, Inc.✕ ECOR · #19,820 in the world | Nephros, Inc.✕ NEPH · #22,480 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments | Medical Instruments |
| Founded | — | — |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | electroCore, Inc. | Nephros, Inc. |
|---|---|---|
| 2025 | $32 MSEC | $19 MSEC |
| 2024 | $25 MSEC | $14 MSEC |
| 2023 | $16 MSEC | $14 MSEC |
| 2022 | $9 MSEC | $10 MSEC |
| 2021 | $5 MSEC | $10 MSEC |
| 2020 | $4 MSEC | $9 MSEC |
| 2019 | $2 MSEC | $10 MSEC |
| 2018 | $1 MSEC | $6 MSEC |
| 2017 | $1 MSEC | $4 MSEC |
| 2016 | — | $2 MSEC |
| 2015 | — | $2 MSEC |
| 2014 | — | $2 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $75 M |
| $36 M |
| Revenue | $32 M | $19 M |
|---|
| Net income | $-14 M | $1 M▲ best |
|---|
| Employees | 83 | 36 |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | — | 18.7× |
| Price to sales | 2.0× | 1.6× |
| Price to book | — | 3.5× |
| Free cash flow yield | -11.0% | -1.6%▲ best |
| Profitability | ||
|---|---|---|
| Gross margin | 86.8%▲ best | 61.8% |
| Operating margin | -41.1% | 6.1%▲ best |
| Net margin | -43.6% | 6.3%▲ best |
| Return on equity | — | 12.7% |
| Growth | ||
|---|---|---|
| Revenue growth | 27.2% | 32.7%▲ best |
| Revenue growth, 3 years a year | 55.1%▲ best | 23.5% |
| Earnings per share growth | — | 1000.0% |
| Cash | ||
|---|---|---|
| Free cash flow margin | -25.8% | — |
| Altman Z-score zone | distress | distress |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.